Julie M. Garcia

Julie M. Garcia

Auto-generated profile, based on publicly available information

Julie M. Garcia

Department of Microbiology and Immunology, University of California, San Francisco, San Francisco, CA 94143, USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
AHAxel Hyrenius-Wittsten
Axel Hyrenius-Wittsten
YSYang Su
Yang Su
MPMinhee Park
Minhee Park
JGJulie M. Garcia
Julie M. Garcia
JAJosef Alavi
Josef Alavi
KRKole T. Roybal
Kole T. Roybal
SynNotch CAR circuits targeting specific solid tumor antigens enhance specificity and improve therapeutic efficacy by regulating T cell exhaustion.

9 November 2022 in Science Translational Medicine
Verified
Journal Article
Open access
DGDaniel B. Goodman
Daniel B. Goodman
CACamillia S. Azimi
Camillia S. Azimi
KKKendall Kearns
Kendall Kearns
ATAlexis Talbot
Alexis Talbot
KGKiavash Garakani
Kiavash Garakani
KRKole T. Roybal
Kole T. Roybal
Chimeric antigen receptors (CARs) repurpose natural signaling components to retarget T cells to refractory cancers but have shown limited efficacy in persistent, recurrent malignancies. Here, we introduce “CAR Pooling,” a multiplexed approach to rapidly identify CAR designs with clinical potential. Forty CARs with signaling domains derived from a range of immune cell lineages were evaluated in pooled assays for their ability to stimulate critical T cell effector functions during repetitive stimulation that mimics long-term tumor antigen exposure. Several domains were identified from the tumor necrosis factor (TNF) receptor family that have been primarily associated with B cells. CD40 enhanced proliferation, whereas B cell–activating factor receptor (BAFF-R) and transmembrane activator and CAML interactor (TACI) promoted cytotoxicity. These functions were enhanced relative to clinical benchmarks after prolonged antigen stimulation, and CAR T cell signaling through these domains fell into distinct states of memory, cytotoxicity, and metabolism. BAFF-R CAR T cells were enriched for a highly cytotoxic transcriptional signature previously associated with positive clinical outcomes. We also observed that replacing the 4-1BB intracellular signaling domain with the BAFF-R signaling domain in a clinically validated B cell maturation antigen (BCMA)–specific CAR resulted in enhanced activity in a xenotransplant model of multiple myeloma. Together, these results show that CAR Pooling is a general approach for rapid exploration of CAR architecture and activity to improve the efficacy of CAR T cell therapies.